{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:55:06Z","timestamp":1777416906772,"version":"3.51.4"},"reference-count":48,"publisher":"SAGE Publications","issue":"12","license":[{"start":{"date-parts":[[2000,12,1]],"date-time":"2000-12-01T00:00:00Z","timestamp":975628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2000,12]]},"abstract":"<jats:sec>\n                    <jats:title>OBJECTIVE:<\/jats:title>\n                    <jats:p>To review the antimicrobial activity, pharmacokinetics, clinical efficacy, and tolerability of cefdinir, an expanded-spectrum oral cephalosporin.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SOURCES:<\/jats:title>\n                    <jats:p>Literature was identified by a MEDLINE search (January 1983\u2013November 1999) of the medical literature, review of English-language literature and bibliographies of these articles, and product information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>STUDY SELECTION:<\/jats:title>\n                    <jats:p>Clinical efficacy data were selected from all published trials mentioning cefdinir. Additional information concerning in vitro susceptibility, safety, chemistry, and pharmacokinetic profile of cefdinir was also reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>DATA SYNTHESIS:<\/jats:title>\n                    <jats:p>Cefdinir, an oral expanded-spectrum cephalosporin, has a broad spectrum of activity against many gram-negative and -positive aerobic organisms, including Streptococcus pneumoniae, Staphylococcus aureus, Streptococcus pyogenes, Haemophilus influenzae, and Moraxella catarrhalis. Cefdinir is stable to hydrolysis by many common \u03b2-lactamases. Cefdinir is rapidly absorbed from the gastrointestinal tract and is primarily eliminated via renal clearance of unchanged drug. The terminal disposition half-life of cefdinir is approximately 1.5 hours. Efficacy has been demonstrated in a number of clinical trials in adults and children with upper and lower respiratory tract infections (e.g., pharyngitis, sinusitis, acute otitis media, acute bronchitis, acute exacerbation of chronic bronchitis, community-acquired pneumonia) and skin and skin-structure infections. The adverse event profile is similar to that of comparator agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Cefdinir is a second-line alternative to first-line antimicrobial agents, with convenient once- or twice-daily dosing in the treatment of upper and lower respiratory tract infections and skin and skin-structure infections. Similar to other oral expanded-spectrum cephalosporins, cefdinir has activity against common pathogens of the respiratory tract and skin and is stable in the presence of many \u03b2-lactamases. The clinical choice of an oral expanded-spectrum cephalosporin will be based on patient acceptance, frequency of administration, and cost.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1345\/aph.19407","type":"journal-article","created":{"date-parts":[[2003,6,3]],"date-time":"2003-06-03T16:52:36Z","timestamp":1054659156000},"page":"1469-1477","source":"Crossref","is-referenced-by-count":13,"title":["Cefdinir: An Expanded-Spectrum Oral Cephalosporin"],"prefix":"10.1177","volume":"34","author":[{"given":"David RP","family":"Guay","sequence":"first","affiliation":[{"name":"David RP Guay PharmD FCP FCCP FASCP CGP, Professor, Institute for the Study of Geriatric Pharmacotherapy, College of Pharmacy, University of Minnesota, Minneapolis, MN; Clinical Specialist, PartneringCare Senior Services, HealthPartners, Minneapolis, MN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2000,12,1]]},"reference":[{"key":"bibr-bibr1-aph.19407","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.41.828"},{"key":"bibr-bibr2-aph.19407","volume-title":"Omnicef (cefdinir)","year":"1999"},{"key":"bibr-bibr3-aph.19407","doi-asserted-by":"publisher","DOI":"10.1159\/000239176"},{"key":"bibr-bibr4-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.12.2652"},{"key":"bibr-bibr5-aph.19407","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/42.4.427"},{"key":"bibr-bibr6-aph.19407","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/36.6.911"},{"key":"bibr-bibr7-aph.19407","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/28.2.239"},{"key":"bibr-bibr8-aph.19407","doi-asserted-by":"publisher","DOI":"10.1159\/000239111"},{"key":"bibr-bibr9-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(92)90105-3"},{"key":"bibr-bibr10-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(91)90069-R"},{"key":"bibr-bibr11-aph.19407","doi-asserted-by":"publisher","DOI":"10.1159\/000239177"},{"key":"bibr-bibr12-aph.19407","first-page":"862","volume":"48","author":"Tomino Y","year":"1998","journal-title":"Arzneimittelforschung"},{"key":"bibr-bibr13-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.33.10.1795"},{"key":"bibr-bibr14-aph.19407","doi-asserted-by":"publisher","DOI":"10.1007\/BF01961677"},{"key":"bibr-bibr15-aph.19407","first-page":"51","volume":"19","author":"Garcia-Rodriguez JA","year":"1993","journal-title":"Drugs Exp Clin Res"},{"key":"bibr-bibr16-aph.19407","doi-asserted-by":"publisher","DOI":"10.7164\/antibiotics.41.1873"},{"key":"bibr-bibr17-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(94)90131-7"},{"key":"bibr-bibr18-aph.19407","doi-asserted-by":"publisher","DOI":"10.1179\/joc.1996.8.3.193"},{"key":"bibr-bibr19-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(92)90072-2"},{"key":"bibr-bibr20-aph.19407","first-page":"225","volume":"18","author":"Payne DJ","year":"1992","journal-title":"Drugs Exp Clin Res"},{"key":"bibr-bibr21-aph.19407","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/34.1.161"},{"key":"bibr-bibr22-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/0732-8893(91)90011-4"},{"key":"bibr-bibr23-aph.19407","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/35.1.53"},{"key":"bibr-bibr24-aph.19407","doi-asserted-by":"publisher","DOI":"10.1159\/000239198"},{"key":"bibr-bibr25-aph.19407","first-page":"319","volume":"18","author":"Blandino G","year":"1992","journal-title":"Drugs Exp Clin Res"},{"key":"bibr-bibr26-aph.19407","doi-asserted-by":"publisher","DOI":"10.1099\/00222615-38-2-114"},{"key":"bibr-bibr27-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.5.858"},{"key":"bibr-bibr28-aph.19407","first-page":"43","volume":"20","author":"Labia R","year":"1994","journal-title":"Drugs Exp Clin Res"},{"key":"bibr-bibr29-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.30.4.1022-1023.1992"},{"key":"bibr-bibr30-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/S0732-8893(96)00217-9"},{"key":"bibr-bibr31-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/0731-7085(95)01687-2"},{"key":"bibr-bibr32-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.5.1082"},{"key":"bibr-bibr33-aph.19407","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/37.2.331"},{"key":"bibr-bibr34-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.7.1718"},{"key":"bibr-bibr35-aph.19407","doi-asserted-by":"publisher","DOI":"10.1001\/archpedi.1997.02170380049008"},{"key":"bibr-bibr36-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.4.739"},{"key":"bibr-bibr37-aph.19407","doi-asserted-by":"publisher","DOI":"10.1007\/BF01709584"},{"key":"bibr-bibr38-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.5.1073"},{"key":"bibr-bibr39-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1517"},{"key":"bibr-bibr40-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(98)80088-X"},{"key":"bibr-bibr41-aph.19407","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.41.7.1579"},{"key":"bibr-bibr42-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(96)80213-X"},{"key":"bibr-bibr43-aph.19407","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(95)70235-0"},{"key":"bibr-bibr44-aph.19407","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.5.2447"},{"key":"bibr-bibr45-aph.19407","doi-asserted-by":"publisher","DOI":"10.1159\/000239213"},{"key":"bibr-bibr46-aph.19407","doi-asserted-by":"publisher","DOI":"10.1007\/BF01967107"},{"key":"bibr-bibr47-aph.19407","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1993.178"},{"key":"bibr-bibr48-aph.19407","volume-title":"1999 Drug topics red book","year":"1999"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.19407","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1345\/aph.19407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:02:56Z","timestamp":1777374176000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1345\/aph.19407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,12]]},"references-count":48,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2000,12]]}},"alternative-id":["10.1345\/aph.19407"],"URL":"https:\/\/doi.org\/10.1345\/aph.19407","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2000,12]]}}}